The Ministry of Health has announced a downward revision of the prices of several essential medicines, a decision which is part of a policy aimed at making medical treatments more accessible for citizens. This drop in prices mainly concerns drugs used to treat chronic pathologies, expensive oncology treatments and injectable products, which have a direct impact on patients’ quality of life.
The selling prices of certain medicines have been adjusted downwards, with reductions ranging from a few dirhams to several hundred dirhams per box. Among the drugs concerned, we find products used in the treatment of cardiovascular diseases, diabetes, as well as treatments for autoimmune diseases. For example, drugs like Durogesic and Enbrel, used for the management of chronic pain and inflammatory diseases, are seeing substantial price reductions, reducing costs for patients and healthcare systems.
The adjusted prices are part of a periodic review aimed at improving the accessibility of medicines on the market. The Ministry of Health specified that these price reductions follow an in-depth study of the Moroccan pharmaceutical market, taking into account both production costs and prices in other countries.
The objective of this policy is twofold. On the one hand, it aims to reduce the financial burden on patients, particularly those from the middle and disadvantaged classes, by making medicines more affordable. On the other hand, it allows the Moroccan health system to better manage expenses related to medicines while guaranteeing market supply.
The government is putting in place strategies to ensure that this drop in prices does not lead to a shortage of medicines. Discussions are underway with pharmaceutical laboratories to guarantee constant supply and avoid market shortages, especially during periods of high demand.
Public reaction has been largely positive, especially for patients who rely on long-term treatment. Patients with chronic illnesses, such as hypertension, diabetes, and arthritis, have expressed relief at this reduction, which allows them to better manage their healthcare expenses. These price adjustments are seen as an important step towards reducing inequalities in access to care in the country.
However, this decision also has implications for the pharmaceutical industry. Laboratories will now have to adapt their profit margins, which could lead to tensions in negotiations between the government and players in the sector. Some observers believe that this measure could encourage drug manufacturers to review their production and distribution strategies, or even turn to more profitable products.
Voices in the pharmaceutical sector are also concerned about the effects on innovation. Some fear that excessive price reductions could discourage investment in the research and development of new treatments, particularly in the areas of specialized medicine.
Belgium
Related News :